Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA;; Weill Cornell Medical College, New York, NY, USA.
² Department of Health and Medical Sciences, Biotech Research and Innovation Centre, University of Copenhagen, Denmark.
³ Washington University, St. Louis, MO, USA.
⁴ Southwestern Medical Center, Dallas, TX, USA.
⁵ University of Edinburgh, Edinburgh, UK.
⁶ Mayo Clinic, Rochester, MN, USA.
⁷ Massachusetts General Hospital, Boston, MA, USA.
⁸ Koch Institute at the Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ MD Anderson, Houston, TX, USA.
¹⁰ UCSF, San Francisco, California, USA.
¹¹ University of Pennsylvania, Philadelphia, PA, USA.
¹² University of Michigan, Ann Arbor, MI, USA.
¹³ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁴ Mount Sinai Hospital, New York, NY, USA.
¹⁵ Chulalongkorn University, Bangkok, Thailand.
¹⁶ University of Manchester, Manchester, UK.
¹⁷ Brigham and Women's Hospital, Boston, MA, USA.
¹⁸ Cholangiocarcinoma Foundation, Salt Lake City, UT, USA.

Ghassan K Abou-Alfa et al. J Gastrointest Oncol. 2016 Dec.

. 2016 Dec;7(6):819-827.

doi: 10.21037/jgo.2016.11.11.

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA;; Weill Cornell Medical College, New York, NY, USA.
² Department of Health and Medical Sciences, Biotech Research and Innovation Centre, University of Copenhagen, Denmark.
³ Washington University, St. Louis, MO, USA.
⁴ Southwestern Medical Center, Dallas, TX, USA.
⁵ University of Edinburgh, Edinburgh, UK.
⁶ Mayo Clinic, Rochester, MN, USA.
⁷ Massachusetts General Hospital, Boston, MA, USA.
⁸ Koch Institute at the Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ MD Anderson, Houston, TX, USA.
¹⁰ UCSF, San Francisco, California, USA.
¹¹ University of Pennsylvania, Philadelphia, PA, USA.
¹² University of Michigan, Ann Arbor, MI, USA.
¹³ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
¹⁴ Mount Sinai Hospital, New York, NY, USA.
¹⁵ Chulalongkorn University, Bangkok, Thailand.
¹⁶ University of Manchester, Manchester, UK.
¹⁷ Brigham and Women's Hospital, Boston, MA, USA.
¹⁸ Cholangiocarcinoma Foundation, Salt Lake City, UT, USA.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

1. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-5. 10.1200/JCO.2011.35.6519 - DOI - PubMed
1. Chong DQ, Zhu AX. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget 2016. [Epub ahead of print]. - PMC - PubMed
1. 2016 Annual Conference. Available online: http://cholangiocarcinoma.org/misc/2016-cholangiocarcinoma-foundation-an...
1. Rosen CB, Darwish Murad S, Heimbach JK, et al. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J Am Coll Surg 2012;215:31-8; discussion 38-40. 10.1016/j.jamcollsurg.2012.03.014 - DOI - PubMed
1. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012;30:1934-40. 10.1200/JCO.2011.40.5381 - DOI - PubMed